Adamas Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Adamas Pharmaceuticals generated cash of -$50,708,000, which is more than the previous year. Cash used in financing activities reached the amount of $1,654,000 last year. Net change in cash is therefore $5,886,000.
Cash Flow
| 2012 | 51.96M | -24K | 7.90M |
|---|---|---|---|
| 2013 | 26.80M | -167K | -3.97M |
| 2014 | 26.19M | -97.38M | 47.02M |
| 2015 | -47.21M | 8.05M | 10.81M |
| 2016 | -48.06M | -26.70M | 65.40M |
| 2017 | -66.82M | 25.56M | 108.84M |
| 2018 | -104.22M | -69.33M | 138.85M |
| 2019 | -80.77M | 88.86M | 1.08M |
| 2020 | -50.70M | 54.94M | 1.65M |
ADMS Cash Flow Statement (2012 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 65.77M | 56.60M | 91.31M | 23.73M | 33.10M | 61.44M | 85.61M | 62.95M | 3.11M |
Operating activities | |||||||||
Net income | -57.40M | -105.18M | -130.99M | -89.49M | -60.05M | -51.80M | 10.22M | 50.92M | 17.73M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 851K | 1.21M | 1.46M | 1.19M | 808K | 435K | 155K | 66K | 41K |
Stock-based compensation expense | 6.43M | 12.85M | 15.78M | 13.36M | 10.57M | 9.95M | 7.20M | 640K | 797K |
| Deferred income tax benefit | 6.43M | 12.85M | 15.78M | 13.36M | 10.57M | 9.95M | 7.20M | 640K | 797K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | -2.27M | -259K | -5.14M | 427K | 490K | -760K | -395K | 761K | -516K |
Inventories | -2.20M | -970K | -3.27M | -1.64M | -102.37M | -109.43M | -82.91M | -25.31M | 0 |
Accounts payable | -4.97M | 398K | 2.75M | 333K | 502K | -788K | 1.52M | -1.15M | 1.79M |
Cash generated by operating activities | -50.70M | -80.77M | -104.22M | -66.82M | -48.06M | -47.21M | 26.19M | 26.80M | 51.96M |
Investing activities | |||||||||
Purchases Of Investments | -68.93M | -93.86M | -200.35M | -62.51M | -103.52M | -59.82M | -96.09M | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -18K | -1.06M | -1.25M | -1.62M | -1.39M | -1.28M | -167K | -24K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 54.94M | 88.86M | -69.33M | 25.56M | -26.70M | 8.05M | -97.38M | -167K | -24K |
Financing activities | |||||||||
Common Stock Issued | 1.04M | 0 | 134.26M | 0 | 61.82M | 9.65M | 42.63M | 21K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | -370K | 0 | 0 |
Repayments of term debt | -2.65M | 0 | 0 | 0 | 0 | 0 | 0 | -4M | 0 |
Cash used in financing activities | 1.65M | 1.08M | 138.85M | 108.84M | 65.40M | 10.81M | 47.02M | -3.97M | 7.90M |
Net Change In Cash | 5.88M | 9.16M | -34.71M | 67.58M | -9.36M | -28.34M | -24.16M | 22.65M | 59.84M |
Cash at end of period | 71.66M | 65.77M | 56.60M | 91.31M | 23.73M | 33.10M | 61.44M | 85.61M | 62.95M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |